Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Return on Equity (2021 - 2025)

Historic Return on Equity for Gain Therapeutics (GANX) over the last 5 years, with Q3 2025 value amounting to 4.56%.

  • Gain Therapeutics' Return on Equity fell 24700.0% to 4.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.56%, marking a year-over-year decrease of 24700.0%. This contributed to the annual value of 2.3% for FY2024, which is 8700.0% down from last year.
  • Per Gain Therapeutics' latest filing, its Return on Equity stood at 4.56% for Q3 2025, which was down 24700.0% from 4.46% recorded in Q2 2025.
  • Gain Therapeutics' 5-year Return on Equity high stood at 0.2% for Q2 2021, and its period low was 4.56% during Q3 2025.
  • For the 5-year period, Gain Therapeutics' Return on Equity averaged around 1.72%, with its median value being 1.68% (2023).
  • As far as peak fluctuations go, Gain Therapeutics' Return on Equity surged by 3200bps in 2024, and later plummeted by -24700bps in 2025.
  • Over the past 5 years, Gain Therapeutics' Return on Equity (Quarter) stood at 0.38% in 2021, then crashed by -121bps to 0.85% in 2022, then plummeted by -168bps to 2.27% in 2023, then decreased by -25bps to 2.82% in 2024, then crashed by -62bps to 4.56% in 2025.
  • Its last three reported values are 4.56% in Q3 2025, 4.46% for Q2 2025, and 3.57% during Q1 2025.